TACKLING THE CORONAVIRUS

We are working across our company and in partnership with others to fight the evolving threat of COVID-19.

Tackling the Coronavirus

Aug 26 2020

As the coronavirus (COVID-19) continues spreading around the globe, companies are stepping up to help fight the evolving threat.

Abbott is working to support communities worldwide with resources and technologies to keep people healthy. We're leveraging decades of experience tracking viruses, leadership in diagnostic tests, expertise in science-based nutrition, and a long history of providing humanitarian relief around the world.

 Detecting the virus with diagnostics

Abbott has launched six tests for COVID-19 (three molecular, one antigen — which pairs with an optional mobile app — and two serology tests) all of which received emergency use authorization (EUA) from the U.S. Food and Drug Administration.

Our molecular tests, which help identify active infections, include the Alinity m molecular test and m2000 RealTime system, which conduct large-scale, high-volume testing in central laboratories and hospitals, and our point-of-care test that’s used on our lightweight ID NOW platform. The ID NOW test delivers positive test results in as little as five minutes and negative results in 13 minutes and can be used in a wide range of settings, including physicians’ offices, urgent care clinics and hospital emergency departments. 

As the virus begins multiplying, our rapid antigen test — BinaxNOW COVID-19 Ag Card— detects antigens (proteins on the outside of the virus). This test, which helps identify active infections in 15 minutes, and is highly portable, easy-to-use and affordable, can be used in a number of near-patient settings outside the hospital.

People who test negative will get a temporary encrypted digital health pass with a QR code through our new, optional, first-of-its-kind NAVICA app, which is available at no charge for iPhone and Android devices. Organizations where people gather, such as workplaces and schools will be able to view and verify the information on a mobile device to facilitate entry into facilities along with hand-washing, social distancing, enhanced cleaning and mask-wearing.

Our Alinity i antibody test — also known as a  serology test — joins ARCHITECT to help detect proteins the body produces in the late stages of infection that may remain for months and possibly years after a person has recovered. Detecting the IgG antibody to SARS-CoV-2 will help determine if a person was previously infected with the virus that causes COVID-19.

"We continue to contribute in a significant and meaningful way by providing new solutions across our diagnostics testing platforms," said Robert B. Ford, president and chief executive officer, Abbott. "I'm extremely proud of the many Abbott people who are working around the clock to get as many tests as we can to healthcare workers and patients."

Abbott has long been a global leader in infectious disease testing, including the development of the first HIV test. The company created a Global Surveillance Program 25 years ago to monitor HIV and hepatitis viruses and identify mutations to ensure our tests remain up to date. Abbott also has a long-standing discovery program that identifies new or unknown pathogens and develops tests to address these new threats.

Providing science-based nutrition

Beyond diagnostics, our scientists in nutrition are focused on creating products that will hydrate and nourish your body. Oral nutrition shakes, like Abbott's Ensure or Glucerna, can help supplement your diet when you need it most and contain nutrients that are key to immune system health, including antioxidants (such as vitamins C, E and selenium), vitamins A and D and zinc.

Hydration is another vital component for good health. But when you're sick, sometimes water's just not enough. Oral rehydration solutions, like our own Pedialyte, provide an optimal balance of electrolytes and glucose, to help replace what's lost during illness.

Caring for people with diabetes

People with underlying health conditions such as diabetes have an increased risk for severe COVID-19-associated illness, according to the Centers for Disease Control and Prevention (CDC). In fact, more than 50% of people with diabetes who were diagnosed with COVID-19 in the U.S. as of March 28 were hospitalized, according to a CDC report.

To help advance their care, Abbott’s FreeStyle Libre 14 day system can now be used in hospitals to remotely monitor glucose levels and glucose history of those with diabetes who can scan by themselves. To ramp up access to our continuous glucose monitoring technology, we’re partnering with the American Diabetes Association and other organizations to donate 25,000 FreeStyle Libre 14 day sensors to U.S. hospitals and medical centers in COVID-19 hotspots.

For important safety information: https://www.freestylelibre.us/safety-information.html

Maintaining access to our technologies and products

Every one of our 107,000 colleagues around the world understands the important role Abbott medical devices, diagnostics, medicines and nutrition products play in people's daily lives – and the responsibility we have to provide continued access when they're needed most. That's why we're continuing to monitor and closely manage inventory levels of finished products, key manufacturing components and critical raw materials at multiple levels throughout the manufacturing supply chain. While no one can predict the course of the pandemic, we're deeply experienced in successfully managing and minimizing disruption to our product supply.

Supporting families and health workers

Our commitment goes beyond just scientific expertise. Families, frontline health workers and communities affected by the pandemic need support. That's why Abbott and its foundation, the Abbott Fund, are supporting relief efforts globally, providing millions in funding and products to help address key needs. This includes working with relief partner organizations to provide frontline health workers with training and resources to advance testing and care, supporting families with needed supplies and information for the prevention and care of COVID-19, and helping meet critical local needs in communities where our employees live and work.

Protecting our people

As a healthcare company, Abbott has been designated as an essential business so we can continue providing an uninterrupted supply of vital diagnostics, medical devices, medicines and nutritional products to our customers. To help keep our own people safe, we've taken steps at our sites to limit exposure, implement social distancing and further enhance the safety of our facilities for the employees onsite.

We're also assisting Abbott families whose lives have been disrupted by COVID-19. The Clara Abbott Foundation provides financial grants to employees who are experiencing economic hardship resulting from unexpected expenses, such as loss of a family member's income, child care and transportation costs and medical expenses.

We're closely monitoring ongoing developments with coronavirus globally and will continue to assess and respond to needs in the days and months ahead.

 This story was originally published on April 7, 2020. It was updated in April to include reference to our announcement on Abbott's launch of its third COVID-19 test, a laboratory-based antibody blood test and for our announcement on Abbott's FreeStyle Libre 14 day system becoming available in the U.S. for hospitalized patients with diabetes during the COVID-19 pandemic. It was further updated on April 27, 2020 to include references that Abbott received U.S. FDA emergency use authorization and CE Mark for its antibody IgG blood test. It was updated May 15 to include Alinity i and Alinity m's EUA from the FDA. It was updated on August 26 to include reference to our announcement on Abbott's launch of its sixth COVID-19 test, a rapid antigen test and an optional companion mobile app.

 

Reference
1. All ARCHITECT analyzers are Class 1 laser products.

 

true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?